International Stem Cell (ISCO) Payables (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Payables of $3.5 million for Q4 2025, down 2.04% year-over-year from $3.6 million in Q4 2024, and down 1.74% quarter-over-quarter from $3.6 million in Q3 2025.
International Stem Cell (ISCO) Payables (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Payables for 16 consecutive years, with $3.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Payables fell 2.04% year-over-year to $3.5 million; the TTM figure through Dec 2025 stood at $3.5 million (down 2.04% YoY), while the FY2025 annual figure was $3.5 million, down 2.04% from the prior year.
- Payables eased to $3.5 million in Q4 2025 per ISCO's latest filing, from $3.6 million in the prior quarter.
- Across five years, Payables topped out at $3.9 million in Q2 2024 and bottomed at $3.4 million in Q2 2021.
- Historically, Payables has averaged $3.7 million across 5 years, with a median of $3.7 million in 2022.
- Annual changes were most pronounced in 2021 — Payables soared 858.61% — and 2024, when it fell 6.28%.
- International Stem Cell's Payables stood at $3.5 million in 2021, then advanced by 5.68% to $3.6 million in 2022, then climbed by 4.77% to $3.8 million in 2023, then slipped by 6.28% to $3.6 million in 2024, then dropped by 2.04% to $3.5 million in 2025.
- Business Quant data shows ISCO's Payables at $3.5 million in Q4 2025, $3.6 million in Q3 2025, and $3.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | 3.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.57 Mn |
| Dec 31, 2025 | 3.51 Mn |
| Sep 30, 2025 | 3.57 Mn |
| Jun 30, 2025 | 3.67 Mn |
| Mar 31, 2025 | 3.89 Mn |
| Dec 31, 2024 | 3.58 Mn |
| Sep 30, 2024 | 3.68 Mn |
| Jun 30, 2024 | 3.90 Mn |
| Mar 31, 2024 | 3.85 Mn |
| Dec 31, 2023 | 3.82 Mn |
| Sep 30, 2023 | 3.73 Mn |
| Jun 30, 2023 | 3.72 Mn |
| Mar 31, 2023 | 3.71 Mn |
| Dec 31, 2022 | 3.65 Mn |
| Sep 30, 2022 | 3.67 Mn |
| Jun 30, 2022 | 3.74 Mn |
| Mar 31, 2022 | 3.86 Mn |
| Dec 31, 2021 | 3.45 Mn |
| Sep 30, 2021 | 3.52 Mn |
| Jun 30, 2021 | 3.35 Mn |